Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis

Drug Delivery

Volumn 18, Issue 1, 2011, Pages 65-73

  Kumar, Gaurav ^a   Sharma, Sadhna ^a   Shafiq, Nusrat ^a   Pandhi, Promila ^a   Khuller, Gopal Krishan ^a   Malhotra, Samir ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Bioavailability; Compliance; Drug delivery; Encapsulation; Ethionamide; Nanoparticles; Oral absorption; Pharmacokinetics; Poly (lactide co glycolide); Sustained release; Tuberculosis

Indexed keywords

ETHIONAMIDE; NANOPARTICLE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; FEMALE; LIVER; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; ETHIONAMIDE; FEMALE; LACTIC ACID; MALE; MICE; NANOCAPSULES; PARTICLE SIZE; POLYGLYCOLIC ACID; TISSUE DISTRIBUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 78650096718     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.509367     Document Type: Article

References (28)

1. Auclair, B., Nix, D.E., Adam, R.D., James, G.T., Peloquin, C.A. (2001). Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother. 45:810-4.
2. Bass, J.B., Jr., Farer, L.S., Hopewell, P.C., O'Brien, R., Jacobs, R.F., Ruben, F., Snider, D.E., Jr., Tornton, G. (1994). Treatment of tuberculosis and tuberculosis infection in adults and children. American thoracic society and the centers for disease control and prevention. Am J Crit Care Med. 149:1359-74.
3. Craig, W.A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26:1-12.
4. Desai, M.P., Labhasetwar, V., Amidon, G.L., Levy, R.J. (1996). Gastrointestinal uptake of biodegradable microparticles: efect of particle size. Pharm Res. 13:1838-45.
5. Drummond, D.C., Noble, C.O., Guo, Z., Hayes, M.E., Park, J.W., Ou, C.-J., Tseng, Y.-L., Hong, K., Kirpotin, D.B. (2009). Improved pharmacokinetics and efcacy of a highly stable nanoliposomal vinorelbine. J Pharm Exp Ter. 328:321-30.
6. Florence, A.T. (1997). Te oral absorption of micro and nanoparticu-lates: neither exceptional nor unusual. Pharm Res. 14:259-65.
7. Florence, A.T. (2005). Nanoparticle uptake by the oral route: fulflling its potential? Dr Discov Today: Technologies. 2:75-81.
8. Frimodt-Moller, N. (2002). How predictive is PK/PD for antibacterial agents. Int J antimicrob agents. 19:333-9.
9. Gronroos, J.A., Toivanen, A. (1964). Blood ethionamide levels after administration of enteric coated and uncoated tablets. Curr Ter Res. 6:105-14.
10. Hariharan, S., Bhardwaj, V., Bala, I., Sitterberg, J., Bakowsky, U., Ravi Kumar, M.N.V. (2006). Design of estradiol loaded PLGA nanopar-ticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res. 23:184-95.
11. Italia, J.L., Bhatt, D.K., Bhardwaj, V., Tikoo, K., Kumar, M.N. (2007). PLGA nanoparticles for oral delivery of cyclosporine: nephrotox-icity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Contr Rel. 119:197-206.
12. James, G.T., McCarthy, E. (1991). Improved high performance liquid chromatographic assay for the determination of ethionamide in serum. J Chromatography. 563:472-5.
13. Kalaria, D.R., Sharma, G., Beniwal, V., Ravi Kumar, M.N.V. (2009). Design of biodegradable nanoparticles for oral delivery of doxo-rubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharmaceutical research. 26:492-501.
14. Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Maincent, P., Kawashima, Y., Lehr, C.M. (2001). Biodegradable nanoparticles for targeted drug delivery in treatment of infam-matory bowel disease. J Pharmacol Exp Ter. 299:775-81.
15. Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M. (2003). Strategies for the assessment of matrix efect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 75:3019-30.
16. Muller, R.H., Jacobs, C., Kayser, O. (2001). Nanosuspensions as particu-late drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliver Rev. 47:3-19.
17. Nahar, M., Mishra, D., Dubey, V., Jain, N.K. (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine. 4:252-61.
18. Norris, D.A., Puri, N., Sinko, P.J. (1998). Te efect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliver Rev. 34:135-54.
19. Pandey, R., Sharma, A., Ahmad, Z., Sharma, S., Khuller, G.K., Prasad, B. (2003a). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 52:981-6.
20. Pandey, R., Zahoor, A., Sharma, S., Khuller, G.K. (2003b). Nanoparticle encapsulated antitubercular drugs as apotential oral drug delivery system against murine tuberculosis. Tuberculosis. 83:373-8.
21. Radwan, M.A., Zaghloul, I.Y., Aly, Z.H. (1999). In vivo performance of parenteral theophylline-loaded polyisobutylcynoacrylate nano-particles in rats. Eur J Pharm Sci. 8:95-8.
22. Rojas, J., Pinto-Alphandary, H., Leo, E., Pecquet, S., Couvreur, P., Fattal, E. (1999). Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly(DL-lactide-co-glycolide) microspheres. Int J Pharm. 183:67-71.
23. Schmidt, S., Barbour, A., Sahre, M., Rand, K.H., Derendorf, H. (2008). PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol. 8:549-56.
24. Veera Reddy, P.R., Vobalaboina, V., Ali, N. (2009). Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannose-grafted amphotericin B lipid nanosphere. J Drug target. 17:140-7.
25. www.fda.gov/CDER/Guidance for industry/ICH Q2B document: Validation of analytical procedures: Methodology/Nov. 1996/Accessed on: 10/07/2008.
26. Weiling, H., Horn, S.W., Hussain, M.D. (2007). Improved bioavailabil-ity of orally administered mifepristone from PLGA nanoparticles. Int J Pharm. 34:173-8.
27. Weinstein, H.J., Hallett, W.Y., Sarauw, A.S. (1962). Te absorption and toxicity of ethionamide. Am Rev Respir Dis. 86:576-8.
28. Zhu, M., Namdar, R., Stambaugh, J.J., Starke, J.R., Bulpitt, A.E., Berning, S.E., Peloquin, C.A. (2002). Population pharmacokinet-ics of ethionamide in patients with tuberculosis. Tuberculosis. 82:91-6.